Jump to Navigation

Facebook Connect

User login

NLA Meetings

Meeting Info

Why attend the Spring CLU:

  • Enhance Your Professional Development
  • Earn Continuing Education Credits
  • Meet World-Class Faculty
  • Learn About the Latest Products and Services
  • Attend Networking Events
  • Prepare for Certification in Clinical Lipidology

Based on this year’s theme, “Achieving New Heights in Lipid Management,” you will learn about the latest controversies in lipid management, the impact of public policy in health care, evolving strategies for prediction and treatment, and emerging targets for atherosclerosis prevention.

Download Meeting Program


KEYNOTE ADDRESS

Janet S. Wright, MD
Detect.Connect.Control. Preventing a Million Together.

Featured Faculty

Allan D. Sniderman, MD
ApoB in Risk Assessment and the Diagnosis and Treatment of the Atherogenic Dyslipoproteinemias


Paul N. Hopkins, MD
Understanding the Molecular Biology of Atherosclerosis: The Future of Prevention and Intervention in Heart Disease


Frank M. Sacks, MD
The ApoC-III Story: Hypertriglyceridemia, Atherogenesis, and Therapeutic Inhibition

Grand Hyatt Denver
1750 Welton Street
Denver, CO 80202

For reservations, please call 1.888.421.1442 and ask for the National Lipid Association's room rate. A special room rate starting at $179 per night plus tax has been arranged. This group rate will be available until January 29, 2015, or until the room block is filled. Please make your reservation early as we do anticipate the room block will sell out.

CME credit provided by the National Lipid Association
This activity has been approved for AMA PRA
Category 1 Credit™
Visit lipid.org for full accreditation information

Pre-Conference Courses:
Venue:
Grand Hyatt Denver

The Grand Hyatt Denver Hotel places you in the heart of all the exciting attractions that make the Mile High City remarkable; from year-round spectator sports, to a wide range of museums and galleries or live theatrical performances. Want to spend the day just relaxing? Unwind in our indoor heated pool or exercise in our StayFit™ gym with a rooftop outdoor jogging track.

To learn more about the hotel, click here.

Friday, February 27, 2015

Session I- Understanding the Impact of Public Policy in Healthcare

3:45 - 4:00 PM Chapter Presidents Welcome & Introduction Paul D. Rosenblit, MD & Kris Vijay, MD
4:00 - 4:30 PM Keynote Address – Detect.Connect.Control. Preventing a Million Together

Janet S. Wright, MD

4:30 - 5:00 PM Clinical Impacts of Cardiovascular Prevention Policy: A Lipidologist’s Perspective

Thomas A. Pearson, MD, PhD, MPH, FNLA

5:00 - 5:30 PM CVD Prevention: Integrated Health System Perspective

Ronald D. Scott, MD

5:30 - 6:00 PM Q&A Panel
6:00 - 7:00 PM Welcome Reception in Exhibit Hall

Saturday, February 28, 2015

Session II- Controversies in Clinical Lipid Management

7:00 - 8:00 AM Breakfast in Exhibit Hall
8:00 - 8:25 AM ACC/AHA CVD Prevention Guidelines Understanding Risk Assessment & Reduction

David C. Goff, Jr., MD, PhD

8:25 - 8:50 AM NLA Recommendations for Patient-Centered Management of Dyslipidemia

Matthew K. Ito, PharmD, FNLA

8:50 - 9:20 AM Two Different Prevention Approaches Two Different Perspectives

Carl E. Orringer, MD, FNLA

9:20 - 9:40 AM Next Steps in Lipid Management: An Expert Panel Discussion
9:40 - 10:00 AM Q&A Panel
10:00 - 10:30 AM Break in Exhibit Hall

Session III- Evolving Strategies and Targets for LDL-C and Non-HDL

10:30 - 11:00 AM Understanding the Molecular Biology of Atherosclerosis: The Future of Prevention and Intervention in Heart Disease

Paul N. Hopkins, MD, MSPH

11:00 - 11:30 AM Inflammation, Risk Prediction, and the Prevention of ASCVD

Paul M. Ridker, MD

11:30 - 12:00 Understanding the Effects of Lipid-lowering Therapy: MRI Studies of Carotid Atherosclerotic Plaques

Xue-Qiao Zhao, MD

12:00 - 12:30 PM Q&A Panel
12:30 - 12:45 PM NLA News & Notes
12:45 - 1:45 PM Lunch in Exhibit Hall

Session IV- Treatment Strategies for Hypertriglyceridemia

1:45 - 2:15 PM The Apolipoprotein C-III Story: Epidemiology, Metabolism, and Basic Science Lead to Treatment

Frank M. Sacks, MD

2:15 - 2:45 PM Absence of Clinical Outcome Trials Treating Moderate or Severe Hypertriglyceridemia: What is a Clinician to Do?

Terry A. Jacobson, MD, FNLA

2:45 - 3:15 PM Clinical Management of Hypertriglyceridemia: State of the Art 2015

Eliot A. Brinton, MD, FNLA

3:15 - 3:45 PM Q&A Panel
3:45 - 4:00 PM Break

Session V- Controversies in Lifestyle Management

4:00 - 4:30 PM The Role of Nutraceutical Supplements in the Treatment of Dyslipidemia and Dyslipidemia-induced Vascular Disease

Mark C. Houston, MD, MS, MSc

4:30 - 5:00 PM Popular Weight Loss Diet Fads and Obesity Guidelines: Is there an Ideal Diet for Weight Reduction?

Geeta Sikand, RD, MA, FNLA

5:00 - 5:30 PM EXERCISE PLEIOTROPHY: Just Move and Move Often

Ralph La Forge, MSc, FNLA

5:30 - 6:00 PM Q&A Panel
6:30 - 9:30 PM FNLA Event

Sunday, March 1, 2015

Session VI-Lipoprotein Particles versus Atherogenic Cholesterol: Which is a Better Target for Atherosclerosis Prevention

8:00 - 8:50 AM Breakfast
9:00 - 9:30 AM ApoB in Risk Assessment and the Diagnosis and Treatment of the Atherogenic Dyslipoproteinemias

Allan D. Sniderman, MD

9:30 - 10:00 AM New Targets and Treatments: Understanding LDL- P, Non- HDL-C , and ApoB

Samia Mora, MD

10:00 - 10:30 AM HDL-C, HDL-P, HDL Function in Relation to Risk Prediction & Treatment

Rachel H. Mackey, PhD, MPH

10:30 - 11:00 AM Q&A Panel
11:00 - AM Adjourn

Upon completion of the educational activity, participants should be able to:

Target Audience

This activity is designed to meet the needs of physicians, physician assistants, pharmacists, registered nurses, nurse practitioners, advance practice registered nurses and registered dietitians with an interest in lipid management.    

Type of Activity
Live Activity
Knowledge (Sessions I, III-IV, VI)
Application (Sessions II, V)

Educational Objectives

At the conclusion of this activity, registered nurses and nurse practitioners should be able to provide appropriate counsel for patients and their families.

At the conclusion of this activity, all participants should be able to:

Session I- Understanding the Impact of Public Policy in Healthcare

  • Discuss the role of collaborations among health system stakeholders in promotion of population health initiatives
  • Describe the strategic direction of public health policy and its impacts on the health care delivery system
  • Describe the potential impact of limiting health care delivery decisions to level 1A evidence in atherosclerosis prevention

Session II- Controversies in Clinical Lipid Management

  • Outline current patient guidelines for the diagnosis, management and treatment of dyslipidemia
  • Define the National Lipid Association’s Recommendations for Patient-Centered Management of Dyslipidemia
  • Compare and contrast the effectiveness of available guidelines for the management of dyslipidemia
  • Apply guidelines into daily practice to help patients reach goals

Session III- Evolving Strategies for ASCVD Prediction and Prevention

  • Critically assess the evidence regarding the utility of inflammatory biomarkers as diagnostic tests for the prevention and treatment of atherosclerosis
  • Review the pathogenesis of atherosclerotic plaque development and progression
  • Review recent clinical trials utilizing aggressive multi-drug lipid-lowering therapies on atherosclerotic plaque composition and clinical outcomes

Session IV- Treatment Strategies for Hypertriglyceridemia

  • Discuss the efficacy and safety of combination lipid drug treatment for the management of hypertriglyceridemia
  • Discuss evidence regarding triglycerides as a risk factor for pancreatitis and cardiovascular disease including the clinical implications for patient management
  • Discuss future targets for management of triglyceride-rich atherogenic cholesterol particles

Session V- Controversies in Lifestyle Management

  • Utilize effective diet and lifestyle strategies for dyslipidemia management
  • Interpret evidence from recent clinical trials of approved omega-3 fatty acids and those in clinical development
  • Outline the impact of various fad, trend and popular diets on short-term and long-term weight loss and atherosclerosis prevention

Session VI- Lipoprotein Particles versus Atherogenic Cholesterol: Which is a Better Target for Atherosclerosis Prevention

  • Evaluate apolipoprotein B (Apo B) as a universal target of atherosclerosis prevention
  • Discuss the assessment and clinical impact of utilizing LDL particle and VLDL particle concentrations (LDL-P and VLDL-P) versus lipoprotein atherogenic cholesterol content in atherosclerosis and residual risk
  • Discuss recent evidence regarding the clinical utility and implications for patient management of HDL particle concentration (HDL-P) versus HDL cholesterol concentration (HDL-C) as a target for CVD risk assessment and modification

 

CME credit provided by the National Lipid Association

Physicians
The National Lipid Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The National Lipid Association designates this live activity for a maximum of 12.00 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in this activity.

Physician Assistants
NCCPA accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.

Dietitians
The National Lipid Association is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). Registered dietitians (RDs) and dietetic technicians, registered (DTRs) will receive 12 continuing professional education units (CPEUs) for completion of this program/ materials. CDR Accredited Provider #NL002.

American Academy of Family Physicians
This Live activity, 2015 Spring Clinical Lipid Update: Achieving New Heights in Lipid Management, with a beginning date of 02/27/2015, has been reviewed and is acceptable for up to   12.00 Elective credit(s) by the American Academy of Family Physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

CE credit provided by Postgraduate Institute for Medicine

Pharmacists

Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Session I- Universal Activity Number 0809-9999-15-006-L01-P (Knowledge)
Postgraduate Institute for Medicine designates this continuing education activity for 2.0 contact hour(s) (.20 CEUs) of the Accreditation Council for Pharmacy Education

Session II- Universal Activity Number 0809-9999-15-007-L01-P (Application)
Postgraduate Institute for Medicine designates this continuing education activity for 2.0 contact hour(s) (.20 CEUs) of the Accreditation Council for Pharmacy Education

Session III – Universal Activity Number 0809-9999-15-008-L01-P (Knowledge)
Postgraduate Institute for Medicine designates this continuing education activity for 2.0 contact hour(s) (.20 CEUs) of the Accreditation Council for Pharmacy Education

Session IV– Universal Activity Number 0809-9999-15-009-L01-P (Knowledge)
Postgraduate Institute for Medicine designates this continuing education activity for 2.0 contact hour(s) (.20 CEUs) of the Accreditation Council for Pharmacy Education

Session V – Universal Activity Number 0809-9999-15-010-L01-P (Application)
Postgraduate Institute for Medicine designates this continuing education activity for 2.0 contact hour(s) (.20 CEUs) of the Accreditation Council for Pharmacy Education

Session VI – Universal Activity Number 0809-9999-15-011-L01-P (Knowledge)
Postgraduate Institute for Medicine designates this continuing education activity for 2.0 contact hour(s) (.20 CEUs) of the Accreditation Council for Pharmacy Education

Nursing
This educational activity for 12.00 contact hours is provided by the Postgraduate Institute for Medicine.
Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Session I- 2.0 credits; Session II- 2.0 credits; Session III- 2.0 credits; Session IV- 2.0 credits; Session V- 2.0 credits; Session VI- 2.0 credits.

Pharmacotherapy contact hours for Advance Practice Registered Nurses to be determined.

Paul D. Rosenblit, MD, PhD, FNLA

President, Pacific Lipid Association
Director, Diabetes/Lipid Management & Research Center
Huntington Beach, CA
Clinical Professor of Medicine
Division of Endocrinology, Diabetes and Metabolism 
University of California, Irvine School of Medicine 
Irvine, CA
Co-Director, Diabetes Out-Patient Clinic
UCI Medical Center
Orange, CA
Diplomate, American Board of Clinical Lipidology

Krishnaswami Vijayaraghavan, MD, FNLA

President, Southwest Lipid Association
Professor of Medicine, Midwestern University, Glendale, Arizona
Vice President, Scottsdale Cardiovascular Center
President, Cardiorenal Society of America
Scottsdale, AZ
Diplomate, American Board of Clinical Lipidology

P. Bart Duell, MD

President- Elect, Pacific Lipid Association
Director, Lipid Disorder Clinic
Director, Lipid-Atherosclerosis Laboratory
Oregon Health and Science University
Portland, OR

Thomas A. Haffey, DO, FNLA

President- Elect, Southwest Lipid Association
Thornton, CO
Diplomate, American Board of Clinical Lipidology

Anne C. Goldberg, MD, FACP, FNLA

Associate Professor of Medicine
Washington University School of Medicine
St. Louis, MO
Diplomate, American Board of Clinical Lipidology

Robert A. Wild, MD, MPH, PhD, FNLA

Professor, Clinical Lipidology and Obstetrics and Gynecology
Oklahoma University Health Sciences Center
Oklahoma City, OK
Diplomate, American Board of Clinical Lipidology

Eliot A. Brinton, MD, FNLA

President, American Board of Clinical Lipidology
Director of Atherometabolic Research
Utah Foundation for Biomedical Research
President, Utah Lipid Center
Salt Lake City, UT
Diplomate, American Board of Clinical Lipidology

David C. Goff, Jr., MD, PhD

Dean, Colorado School of Public Health
University of Colorado at Denver
Aurora, CO

Paul N. Hopkins, MD, MSPH

Professor of Internal Medicine
University of Utah
Salt Lake City, UT
Diplomate, American Board of Clinical Lipidology

Mark C. Houston, MD, MS, MSc

Associate Clinical Professor Medicine
Vanderbilt Medical School
Direction Hypertension Institute
Nashville, TN

Matthew K. Ito, PharmD, FCCP, CLS, FNLA

Immediate Past President, National Lipid Association
Professor of Pharmacy Practice
Oregon State University
Oregon Health & Science University
College of Pharmacy
Portland Campus at Oregon Health & Science University
Portland, OR

Terry A. Jacobson, MD, FNLA

President, National Lipid Association
Director, Office of Health Promotion and Disease Prevention
Professor of Medicine
Emory University
Atlanta, GA
Diplomate, American Board of Clinical Lipidology

Ralph La Forge, MSc, CLS, FNLA

Immediate- Past-President, Southeast Lipid Association
Clinical Exercise Physiologist
Durham, NC

Rachel H. Mackey, PhD, MPH

Assistant Professor of Epidemiology
University of Pittsburgh Graduate School of Public Health
Pittsburgh, PA

Samia Mora, MD

Assistant Professor of Medicine
Division of Preventive Medicine
Brigham and Women’s Hospital
Harvard Medical School
Boston, MA

Carl E. Orringer, MD, FACC, FNLA

President-Elect, National Lipid Association
Associate Professor of Medicine
University of Miami
School of Medicine
Miami, FL
Diplomate, American Board of Clinical Lipidology

Thomas A. Pearson, MD, PhD, MPH, FNLA

Executive Vice President for Research and Education
Professor of Epidemiology and Medicine
University of Florida Health Sciences Center
Gainesville, FL
Diplomate, American Board of Clinical Lipidology

Paul M. Ridker, MD

Senior Physician, Brigham and Women's Hospital
Eugene Braunwald Professor of Medicine,
Harvard Medical School
Boston, MA

 

Frank M. Sacks, MD

Professor of Cardiovascular Disease Prevention,
Nutrition Department,
Harvard School of Public Health;
Professor of Medicine
Harvard Medical School;
Senior Physician,
Channing Division of Network Medicine,
Brigham & Women's Hospital
Boston, MA

Ronald D. Scott, MD

Kaiser Permanente
So Cal CVD Co-Lead
West Los Angeles Medical Center
Los Angeles, CA
Diplomate, American Board of Clinical Lipidology

Geeta Sikand, MA, RDN, CLS, FNLA, FAND

Associate Clinical Professor of Medicine: Cardiology
University of California Irvine School of Medicine
Director of Nutrition,
University of California Irvine Preventive Cardiology Program
Irvine, CA

Allan D. Sniderman, MD

Edwards Professor of Cardiology,
Professor of Medicine
McGill University
Royal Victoria Hospital
Montreal, Canada
Diplomate, American Board of Clinical Lipidology

Janet S. Wright, MD

Executive Director
Million Hearts
Department of Health and Human Services
CDC and CMS
Baltimore, MD

Xue-Qiao Zhao, MD

Research Professor of Medicine
Director, Clinical Atherosclerosis Research Lab
Division of Cardiology
University of Washington
Seattle, WA

Registration for Spring CLU 2015 has ended.

2015 EXHIBITS

Plan now for your company to participate in the National Lipid Association’s Clinical Updates in 2015. Our 3 combined meetings provide you with a unique opportunity to reach our target audience of Lipidologists, Cardiologists, Endocrinologists, Primary Care Physicians and Allied Health Professionals involved in dyslipidemia management, as well as our distinguished board and faculty.

Our numerous sponsorship opportunities allow you to connect with our members in a whole new way, providing you with maximum return on your investment. The exhibit hall provides a unique setting for you and your company’s representatives to interact daily with attendees as they study the latest advances in their professions.

We look forward to your participation and seeing you in 2015!

Download the 2015 CLU Prospectus

Contact:
Theresa Henson
Exhibits Manager
National Lipid Association
6816 Southpoint Parkway, Suite 1000
Jacksonville, FL 32216
Office: 904.998.0854
Direct: 904.309.6207
Fax: 904.998.0854
Email: thenson@lipid.org

Exhibitors will be announced soon.

FNLA Pints and Bites
Saturday, February 28, 2015

DENVER BEER COMPANY
4455 Jason St.
Denver, CO 80211
7:00–9:00 PM
$70 per person (A portion of the cost will go to educational initiatives of the Foundation of the NLA.)
Join us on the evening of February 28 for a beer tasting at Denver Beer Company’s production facility. Learn about some of Denver’s finest brews while mingling with colleagues and friends over heavy hors d’oeuvres from Footer’s Catering. Serving only premium artisan ales and lagers, Denver Beer Company utilize fresh ingredients and embraces both innovative and old world styles of beer.

Transportation will be provided to and from this event.
 

 

Symposia Schedule will be available soon.

2015 SATELLITE SYMPOSIA GUIDELINES

The National Lipid Association (NLA) has established that independently developed and CME/CE certified satellite symposia held in conjunction with the scientific meetings of the NLA are valuable opportunities to provide continuing education for our members. In this regard, we are pleased to offer satellite symposia slots in conjunction with our 2015 Clinical Lipid Updates.

Satellite symposia address educational needs and performance gaps that complement the NLA scientific program agenda. They may include one or a number of speakers and may cover one or several topics addressing the educational gaps of lipid specialists.

The following deadlines and guidelines provide important information about holding a Satellite Symposium at the 2015 Clinical Lipid Updates and the process for completing a symposium proposal. Please contact the NLA business development department directly (contact below) should there be any questions or further information required. See you in 2015!

DOWNLOAD 2015 SATELLITE SYMPOSIA GUIDELINES 2015

Contact:
Amina Resheidat
Program Coordinator
904-309-6212

aresheidat@lipid.org

0
No votes yet

Coming Soon...

0
No votes yet



by Dr. Radut.